Dr. Michael Krenz (Counsel) is a German qualified attorney (Rechtsanwalt) who focuses on complex patent litigation cases across a range of technologies, in particular as part of large cross-border disputes.
He has extensive experience in handling both infringement proceedings before all relevant German courts (trial and appellate level) and validity proceedings before the German Federal Patent Court, German Federal Supreme Court as well as the European Patent Office (Opposition Divisions and Boards of Appeal).
His practice specifically focuses on litigating high-profile cases for researching pharma companies. In this respect, Michael has advised inter alia on cases involving a bi-specific antibody for treatment of cancer, a drug for reduction of thrombotic cardiovascular events (including stent thrombosis), a drug for prevention of migraine and a drug for use in swine breeding for treatment of Coccidiosis as well as prevention of iron deficiency anaemia. Besides that, his experience includes litigating cases in the fields of telecommunication (SEP/FRAND litigation), medical devices, network architecture, video coding, software (operating system and user interface level), micromechanics and printing technologies.
Michael had already worked at Quinn Emanuel from 2010 until 2015. He subsequently worked at two other international law firms and returned to Quinn Emanuel in January 2020. Michael holds degrees of Heidelberg University (JD equivalent) and Tübingen University (PhD, summa cum laude).
- Eli Lilly
- Legal Clerkship at the District Court Heidelberg
(Second State Examination, 2009)
- University of Tuebingen and University of Heidelberg
(Law Studies; First State Examination, 2007)
- Admitted to the Munich Bar (Rechtsanwaltskammer München)
- Allen & Overy
Senior Associate (2017 – 2019)
- Gowling WLG
Senior Associate (2015 – 2017)
- Quinn Emanuel
Associate (2010 – 2015)
- “Das Verbot unwahrer Angaben, Eine Untersuchung des § 5 I 2, 1. Alt. UWG”, Diss. 2015